Zeleciment rostudirsen (z-rostudirsen)

Name: Zeleciment rostudirsen (z-rostudirsen) in Duchenne muscular dystrophy: Economic burden and healthcare resource utilization
Published: 2026-09-14T15:39:06-04:00

Duchenne muscular dystrophy

Also known as DYNE-251

Manufacturer: Dyne Therapeutics
Regulatory submission: BLA submitted May 2026
Launch: Anticipated in the first quarter of 2027
Last updated: September 19, 2026

Section

Product information and disease description Place of product in therapy Disease description Burden of Duchenne muscular dystrophy

Economic burden and healthcare resource utilization

3 evidence topics · 2 sources

DMD economic-burden systematic review

“the mean per-patient annual direct medical cost of illness (in 2025 international US dollars) was estimated at between $2620 and $209,980” (opens the source at this quote in a new tab)

U.S. healthcare costs

“The DMD and non-MD cohorts included 782 matched pairs.” (opens the source at this quote in a new tab)

U.S. healthcare costs: mean total healthcare costs, DMD versus non-MD

“(US$103,826.05 ± 309,335.71 versus US$3225.30 ± 13,865.14; p < 0.0001) per patient per year” (opens the source at this quote in a new tab)